{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5"}]}],"title":"Retreatment 1 (n = 320)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9"}]}],"title":"Retreatment 2 (n = 267)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9"}]}],"title":"Retreatment 3 (n = 234)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4"}]}],"title":"Retreatment 4 (n = 175)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9"}]}],"title":"Retreatment 5 (n = 136)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8"}]}],"title":"Retreatment 6 (n = 92)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"}],"units":"Participants"}],"description":"A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity \\[symptom-free and no arthritis symptoms\\], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). The ACR20 response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.","groups":[{"description":"Participants received rituximab 1 g intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid ≥ 5 mg/week or equivalent, given as either a single dose or as divided daily doses.","id":"OG000","title":"Rituximab"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population: All participants who received any part of an infusion of study medication in study WA17531.","reportingStatus":"POSTED","timeFrame":"Baseline to the end of the retreatment period (up to 7 years, 6 months)","title":"Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}